Newsroom
Pure-DEL has received CHF 150,000 from Venture Kick to target the undruggable
18.11.2025
ETH spin-off Pure-DEL has received CHF 150,000 from Venture Kick to advance its technology for tackling some of the most challenging drug targets. The funding will support the expansion of Pure-DEL’s DNA-Encoded Library (DEL) portfolio, ope ... En savoir plus
CHF 40,000 for AI property management, targeted cancer drugs, and 3D engineering tools
17.11.2025
Bewy, Biodelphis Therapeutics, and nureo were selected in the second stage of Venture Kick’s support program. Their projects include an AI-powered property management platform that streamlines workflows, reduces costs by up to 50%, and prov ... En savoir plus
GlioCART receives CHF 150,000 from Venture Kick to fight the most aggressive form of brain cancer
17.11.2025
GlioCART has obtained CHF 150,000 from Venture Kick to develop a new type of cell therapy – the first CAR-T cell therapy – designed to target both glioblastoma tumors and the surrounding immune-suppressive environment. The spin-off from the ... En savoir plus
Archive Newsletter
Communiqués de Presse
Press review
Forgis erhält CHF 150'000 von Venture Kick
Contact medias
Pour toute question ou demande médias, veuillez envoyer un email à notre équipe de communication. Si vous avez une question d’ordre général sur Venture Kick, veuillez voir notre page contact.
Vous pouvez obtenir davantage d’informations sur Venture Kick ici ou télécharger le rapport annuel ici.